Alterations in the immune response of Human Immunodeficiency Virus (HIV)-infected subjects treated with an HIV-specific protease inhibitor, ritonavir

Journal of Infectious Diseases

Volumn 173, Issue 2, 1996, Pages 321-329

  Kelleher, A D ^a   Carr, A ^a   Zaunders, J ^a   Cooper, D A ^a  

^a ST VINCENT S HOSPITAL   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

RITONAVIR;

ANTIVIRAL ACTIVITY; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFECT; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE RESPONSE; LYMPHOCYTE COUNT; LYMPHOCYTE SUBPOPULATION; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL;

EID: 0030052964     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1093/infdis/173.2.321     Document Type: Article

References (16)

1. Krowka JF, Stites DP, Jain S, et al. Lymphocyte proliferative responses to human immunodeficiency virus antigens in vitro. J Clin Invest 1989;83:1198-203.
2. Wahren B, Morfeldt-Mansson L, Biberfeld G, et al. Impaired specific cellullar response to HTLV-III before other immune defects in patients with HTLV-III infection. N Engl J Med 1986;315:393-4.
3. + cell numbers and clinical staging. J Clin Invest 1989;84:1892-9.
4. + T helper cell depletion occurs. J Clin Invest 1988;82:1908-14.
5. Clerici M, Landay AL, Kessler HA, et al. Reconstitution of long term T-helper cell function after zidovudine therapy in human immunodeficiency virus-infected patients. J Infect Dis 1992;166:723-30.
6. Rinaldo C, Huang XL, Piazza P, et al. Augmentation of cellular immune function during the early phase of zidovudine treatment of AIDS patients. J Infect Dis 1991;164:638-45.
7. Biglino A, Pugliese A, Fomo B, Pollono AM, Busso M, Gioannini P. Effects of long term zidovudine treatment on cell-mediated immune response and lymphokine production. J Acquir Immune Defic Syndr 1991;4:261-6.
8. Yarchoan R, Mitsuya H, Thomas RV, et al. In vitro activity against HIV and favorable toxicity profile of 2′,3′-dideoxyinosine. Science 1989;245:412-5.
9. Clerici M, Roilides E, Butler KM, et al. Changes in T-helper cell function in human immunodeficiency virus-infected children during didanosine therapy as a measure of antiretroviral activity. Blood 1992;80: 2196-202.
10. Dagaglio G, Michel F, Langlade-Demoyen P, et al. Enhancement of HIV-specific cytotoxic T-lymphocyte responses by zidovudine (AZT) treatment. Clin Exp Immunol 1992;87:7-14.
11. Nye KE, Knox KA, Pinching AJ. Lymphocytes from HIV-infected individuals show aberrant inositol polyphosphate metabolism which reverses after zidovudine therapy. AIDS 1991;5:413-7.
12. French MAH, Mallal SA, Dawkins RL. Zidovudine-induced restoration of cell-mediated immunity to mycobacteria in immunodeficient HIV-infected patients. AIDS 1992;6:1293-5.
13. de Martini RM, Turner RR, Formenti SC, et al. Peripheral blood mononuclear cell abnormalities and their relationship to clinical course in homosexual men with HIV infection. Clin Immunol Immunopathol 1988;46:258-71.
14. Fletcher MA, Azen SP, Adelsberg B, et al. Immunophenotyping in a multicenter study: the Transfusion Safety Study Experience. Clin Immunol Immunopathol 1989;52:38-47.
15. van Noesel CJ, Grueters RA, Terpstra FG, Schellekens PTA, van Lier RAW, Miedema F. Functional and phenotypic evidence for a selective loss of memory cells in asymptomatic human immunodeficiency virus-infected men. J Clin Invest 1990;86:293-9.
16. Jaleco AC, Covas MJ, Pinto LA, Victorino RMM. Distinct alterations in the distribution of CD45RO T-cell subset in HIV-2 compared with HIV-1 infection. AIDS 1994;8:1663-8.